Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1819202122232425262728...123124»
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of the American Society of Clinical Oncology (Pubmed Central) -  Jan 21, 2024   
    Currently, chemotherapy based on doxorubicin and ifosfamide is still the first line treatment for patients with advanced soft tissue sarcoma who have distant metastasis...At the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), oncologists from all over the world reported many researches related to the treatment of soft tissue sarcoma. This article aims to review the new progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of ASCO.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Identification of CT values that could be predictive of necrosis in HCC after lenvatinib treatment (New Hall) -  Jan 20, 2024 - Abstract #APASL2024APASL_2706;    
    The cut-off value of 30.2 HU for CTav (N30-CTav) might be appropriate for identifying post-lenvatinib necrosis in HCC, and an N30-CTav occupancy rate of >30.6% might be a predictor of maintenance of CR. Use of these indicators have the potential to impact systemic chemotherapy for HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    M.B., a complex case of unsuccessful TACE: a case report (New Hall) -  Jan 20, 2024 - Abstract #APASL2024APASL_2703;    
    A systemic treatment with Lenvatinib 8mg/die was then started (April 2021), after endoscopic and cardiological studies...The systemic treatment was continued for two years without major toxities, and the TC scan performed at January 2023 showed a complete radiological response. The treatment was then stopped.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    The therapeutic hierarchy strategy or the treatment migration (New Hall) -  Jan 20, 2024 - Abstract #APASL2024APASL_2701;    
    The last follow-up was in November 2023 with TC scan which was complete response. The therapeutic hierarchy strategy or the treatment migration are particularly important in intermediate and advanced stages of hepatocellular carcinoma, when initially curative therapies are usually excluded.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    The Importance of Hepatic Reserve in Sequential Therapy for Unresectable Hepatocellular Carcinoma (New Hall) -  Jan 20, 2024 - Abstract #APASL2024APASL_2638;    
    In this study, we examined the so-called "albumin-bilirubin (ALBI) curve", or the change in ALBI score during Lenvatinib (LEN) treatment...Moreover, at 4 weeks before discontinuation in the non-sequential group ALBI scores worsened to -1.47. Our results suggest that LEN treatment should be discontinued or switched to the sequential therapy when the ALBI score worsens to - 1.47 during the course of treatment in CTP-A uHCC patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date, Tumor mutational burden, Metastases:  Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov) -  Jan 19, 2024   
    P2,  N=40, Recruiting, 
    Finally, sorafenib seemed to perform best for patients with deteriorated liver function. Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date:  Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma (clinicaltrials.gov) -  Jan 18, 2024   
    P2,  N=56, Not yet recruiting, 
    Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes. Trial completion date: Sep 2028 --> Dec 2028 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2026 --> Dec 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PLANE-PC: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Jan 17, 2024   
    P2,  N=50, Recruiting, 
    Trial completion date: Sep 2028 --> Dec 2028 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2026 --> Dec 2026 Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy:  Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (clinicaltrials.gov) -  Jan 16, 2024   
    P2,  N=30, Recruiting, 
    Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Preclinical, Journal, Metastases:  Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line. (Pubmed Central) -  Jan 11, 2024   
    Moreover, HCC-ZJ spontaneously formed pulmonary metastases in the orthotopic tumor model. In summary, a new HCC cell line derived from a patient with alcohol-related HCC was established, which showed a high metastatic capacity and could be applied for in vitro and in vivo experiments during pre-clinical research.Highlights
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (clinicaltrials.gov) -  Jan 11, 2024   
    P2,  N=64, Active, not recruiting, 
    In summary, a new HCC cell line derived from a patient with alcohol-related HCC was established, which showed a high metastatic capacity and could be applied for in vitro and in vivo experiments during pre-clinical research.Highlights Trial completion date: Sep 2023 --> Apr 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, IO biomarker:  Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck. (Pubmed Central) -  Jan 9, 2024   
    In particular, the combination of these agents with immunotherapy is an exciting area that may be a promising option for patients with recurrent or metastatic disease, evidenced in recent trials such as the combination immune checkpoint inhibitors with lenvatinib and cabozantinib. In addition, the use of such combination therapy preoperatively in locally advanced disease is another area of interest.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PECATI: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (clinicaltrials.gov) -  Jan 9, 2024   
    P2,  N=43, Recruiting, 
    In addition, the use of such combination therapy preoperatively in locally advanced disease is another area of interest. Trial completion date: Oct 2023 --> Jan 2026 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  Journal:  Updates on Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) -  Jan 8, 2024   
    In the advanced setting, the evolution from sorafenib as the primary first-line option to new standards, such as atezolizumab/bevacizumab and tremelimumab/durvalumab, to other emerging therapies such as tislelizumab and pembrolizumab with lenvatinib, is explored. Additionally, second-line treatments and insights into the interplay between immunotherapies and antiangiogenic agents, as well as novel combination strategies that add complexity to treatment decisions, are discussed.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Analysis of disease progression in patients who were evaluated as complete response (CR) by mRECIST (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2411;    
    Of patients evaluated as CR by mRECIST, 61% had disease progression. The proportion of PD was significantly higher in the 639 lenvatinib group, suggesting the need for additional therapy or close follow-up.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Multidisciplinary treatment strategy for macroscopic portal vein tumor thrombus (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2383;    
    For Vp3/4 HCC, hepatectomy tended to have a better prognosis than chemotherapy. Future studies are needed to determine the possibility of long-term prognosis for patients in the chemotherapy group who can be treated with conversion therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    A case of rapid deterioration of general condition after discontinuation of sequential treatment. (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2266;    
    Atezolizumab + bevacizumab (ATZ+BEV) started 08/03/2022...Lenvatinib started, but discontinued on 03/10/2023 due to fatigue... Reflecting on the course of treatment for elderly patients with advanced HCC, we reaffirmed the importance of maintaining liver function and PS.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Systemic treatment in patients with unresectable hepatocellular carcinoma in Child-Pugh class B. (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2225;    
    Although both treatments showed equivalent effects, neither demonstrated sufficient therapeutic efficacy in the present cases. Development of an effective systemic therapy for uHCC patients with CP-B is needed in the near future.